PPARD rs7770619 polymorphism in a Korean population: Association with plasma malondialdehyde and impaired fasting glucose or newly diagnosed type 2 diabetes

Minjoo Kim, Minkyung Kim, Hye Jin Yoo, Yao Sun, Sang Hyun Lee, Jong Ho Lee

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Both the peroxisome proliferator-activated receptor delta gene (PPARD) and malondialdehyde plasma concentrations may play a role in impaired glucose metabolism. The aim of this work was to determine whether PPARD is a candidate gene for impaired fasting glucose or type 2 diabetes and whether a particular genetic variant shows association with plasma malondialdehyde levels. Among the 10 single-nucleotide polymorphisms that were most strongly associated with malondialdehyde, the rs7770619 polymorphism in PPARD was analysed in 1798 subjects with normal fasting glucose, impaired fasting glucose and newly diagnosed type 2 diabetes. Our data demonstrate that the CT genotype of the rs7770619 is associated with a lower risk of impaired fasting glucose or type 2 diabetes together with lower plasma levels of malondialdehyde in both groups (p < 0.05). Glucose levels and the rs7770619 are significantly associated in individuals with normal fasting glucose, and a trend towards an association between glucose levels and rs7770619 is also observed in individuals with impaired fasting glucose or type 2 diabetes. In conclusion, PPARD rs7770619 is a novel candidate variant for impaired fasting glucose and type 2 diabetes and shows association with malondialdehyde levels. Future work is required to understand the mechanisms for these associations and the clinical implications of our findings.

Original languageEnglish
Pages (from-to)360-363
Number of pages4
JournalDiabetes and Vascular Disease Research
Volume15
Issue number4
DOIs
Publication statusPublished - 2018 Jul 1

Fingerprint

PPAR delta
Malondialdehyde
Type 2 Diabetes Mellitus
Fasting
Glucose
Population
Genes
Single Nucleotide Polymorphism

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Cardiology and Cardiovascular Medicine

Cite this

@article{494aba5c98bc4173bd733abd6784edcb,
title = "PPARD rs7770619 polymorphism in a Korean population: Association with plasma malondialdehyde and impaired fasting glucose or newly diagnosed type 2 diabetes",
abstract = "Both the peroxisome proliferator-activated receptor delta gene (PPARD) and malondialdehyde plasma concentrations may play a role in impaired glucose metabolism. The aim of this work was to determine whether PPARD is a candidate gene for impaired fasting glucose or type 2 diabetes and whether a particular genetic variant shows association with plasma malondialdehyde levels. Among the 10 single-nucleotide polymorphisms that were most strongly associated with malondialdehyde, the rs7770619 polymorphism in PPARD was analysed in 1798 subjects with normal fasting glucose, impaired fasting glucose and newly diagnosed type 2 diabetes. Our data demonstrate that the CT genotype of the rs7770619 is associated with a lower risk of impaired fasting glucose or type 2 diabetes together with lower plasma levels of malondialdehyde in both groups (p < 0.05). Glucose levels and the rs7770619 are significantly associated in individuals with normal fasting glucose, and a trend towards an association between glucose levels and rs7770619 is also observed in individuals with impaired fasting glucose or type 2 diabetes. In conclusion, PPARD rs7770619 is a novel candidate variant for impaired fasting glucose and type 2 diabetes and shows association with malondialdehyde levels. Future work is required to understand the mechanisms for these associations and the clinical implications of our findings.",
author = "Minjoo Kim and Minkyung Kim and Yoo, {Hye Jin} and Yao Sun and Lee, {Sang Hyun} and Lee, {Jong Ho}",
year = "2018",
month = "7",
day = "1",
doi = "10.1177/1479164118776414",
language = "English",
volume = "15",
pages = "360--363",
journal = "Diabetes and Vascular Disease Research",
issn = "1479-1641",
publisher = "SAGE Publications Ltd",
number = "4",

}

PPARD rs7770619 polymorphism in a Korean population : Association with plasma malondialdehyde and impaired fasting glucose or newly diagnosed type 2 diabetes. / Kim, Minjoo; Kim, Minkyung; Yoo, Hye Jin; Sun, Yao; Lee, Sang Hyun; Lee, Jong Ho.

In: Diabetes and Vascular Disease Research, Vol. 15, No. 4, 01.07.2018, p. 360-363.

Research output: Contribution to journalArticle

TY - JOUR

T1 - PPARD rs7770619 polymorphism in a Korean population

T2 - Association with plasma malondialdehyde and impaired fasting glucose or newly diagnosed type 2 diabetes

AU - Kim, Minjoo

AU - Kim, Minkyung

AU - Yoo, Hye Jin

AU - Sun, Yao

AU - Lee, Sang Hyun

AU - Lee, Jong Ho

PY - 2018/7/1

Y1 - 2018/7/1

N2 - Both the peroxisome proliferator-activated receptor delta gene (PPARD) and malondialdehyde plasma concentrations may play a role in impaired glucose metabolism. The aim of this work was to determine whether PPARD is a candidate gene for impaired fasting glucose or type 2 diabetes and whether a particular genetic variant shows association with plasma malondialdehyde levels. Among the 10 single-nucleotide polymorphisms that were most strongly associated with malondialdehyde, the rs7770619 polymorphism in PPARD was analysed in 1798 subjects with normal fasting glucose, impaired fasting glucose and newly diagnosed type 2 diabetes. Our data demonstrate that the CT genotype of the rs7770619 is associated with a lower risk of impaired fasting glucose or type 2 diabetes together with lower plasma levels of malondialdehyde in both groups (p < 0.05). Glucose levels and the rs7770619 are significantly associated in individuals with normal fasting glucose, and a trend towards an association between glucose levels and rs7770619 is also observed in individuals with impaired fasting glucose or type 2 diabetes. In conclusion, PPARD rs7770619 is a novel candidate variant for impaired fasting glucose and type 2 diabetes and shows association with malondialdehyde levels. Future work is required to understand the mechanisms for these associations and the clinical implications of our findings.

AB - Both the peroxisome proliferator-activated receptor delta gene (PPARD) and malondialdehyde plasma concentrations may play a role in impaired glucose metabolism. The aim of this work was to determine whether PPARD is a candidate gene for impaired fasting glucose or type 2 diabetes and whether a particular genetic variant shows association with plasma malondialdehyde levels. Among the 10 single-nucleotide polymorphisms that were most strongly associated with malondialdehyde, the rs7770619 polymorphism in PPARD was analysed in 1798 subjects with normal fasting glucose, impaired fasting glucose and newly diagnosed type 2 diabetes. Our data demonstrate that the CT genotype of the rs7770619 is associated with a lower risk of impaired fasting glucose or type 2 diabetes together with lower plasma levels of malondialdehyde in both groups (p < 0.05). Glucose levels and the rs7770619 are significantly associated in individuals with normal fasting glucose, and a trend towards an association between glucose levels and rs7770619 is also observed in individuals with impaired fasting glucose or type 2 diabetes. In conclusion, PPARD rs7770619 is a novel candidate variant for impaired fasting glucose and type 2 diabetes and shows association with malondialdehyde levels. Future work is required to understand the mechanisms for these associations and the clinical implications of our findings.

UR - http://www.scopus.com/inward/record.url?scp=85047378647&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047378647&partnerID=8YFLogxK

U2 - 10.1177/1479164118776414

DO - 10.1177/1479164118776414

M3 - Article

C2 - 29776318

AN - SCOPUS:85047378647

VL - 15

SP - 360

EP - 363

JO - Diabetes and Vascular Disease Research

JF - Diabetes and Vascular Disease Research

SN - 1479-1641

IS - 4

ER -